Luratec, a South Korean medical device company specializing in orthopedic implants, has announced its successful export of its CentLoc artificial knee joint to the United States. This marks a significant milestone for the company as it expands its global footprint in the highly competitive orthopedic market.

Through a strategic partnership with Aegis Spine, Luratec’s US-based sales subsidiary, the company has secured a foothold in the world’s largest market for orthopedic implants. The initial shipment of CentLoc devices, valued at $220,000, represents a promising start for the company’s US operations.

Designed specifically for Korean body types, CentLoc has garnered attention for its innovative design and superior performance. By successfully obtaining FDA clearance, Luratec has demonstrated its commitment to meeting the rigorous quality standards required for the US market.

The company’s domestic manufacturing facility in Cheonan, South Chungcheong Province, has played a crucial role in enabling this export achievement. Equipped with state-of-the-art production capabilities, Luratec is well-positioned to meet the growing demand for its products both domestically and internationally.

“We are excited to announce our entry into the US market,” said Jong-Jin Park, CEO of Luratec. “The strong demand for our CentLoc knee replacement from US hospitals is a testament to the quality and innovation of our products. We believe that our partnership with Aegis Spine will drive significant growth for our company in the years to come.”

With its focus on research and development, Luratec is committed to advancing the field of orthopedic implants and improving the lives of patients worldwide. The company’s success in the US market is expected to further solidify its position as a leading player in the global orthopedic industry.